Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.
Vidal N, Climent MÁ, Pérez S, Méndez-Vidal MJ, Anguera G, Martínez Salas I, Gallardo E, Cuéllar-Rivas MA, Molina-Cerrillo J, Martín A, Rodriguez-Vida A, Almagro Casado E, Gonzalez M, Domènech M, Martínez Kareaga M, Fernández Calvo O, Villa Guzmán JC, Vázquez Estévez S, González-Del-Alba A, Puente J. Vidal N, et al. Among authors: cuellar rivas ma. Clin Transl Oncol. 2025 May;27(5):2220-2231. doi: 10.1007/s12094-024-03744-6. Epub 2024 Oct 6. Clin Transl Oncol. 2025. PMID: 39369361
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.
García Del Muro X, Páez López-Bravo D, Cuéllar-Rivas MA, Maroto P, Giannatempo P, Castellano D, Climent MA, P Valderrama B, Gómez de Liaño A, López-Montero L, Mina L, Alcalá-López D, Sampayo-Cordero M, Necchi A. García Del Muro X, et al. Among authors: cuellar rivas ma. Eur Urol Oncol. 2025 Apr;8(2):278-286. doi: 10.1016/j.euo.2024.04.021. Epub 2024 May 15. Eur Urol Oncol. 2025. PMID: 38749903 Clinical Trial.
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Grande E, et al. Among authors: cuellar rivas ma. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405437 Free PMC article. Clinical Trial.